€20m loan for pandemic preparedness

Fab’entech SA specialises in the development and production of therapeutics against biological threats. The  cash infusion will accelerate the development, production, and commercialisation of Fabentech’s broad-spectrum therapeutics, a critical step in protecting public health from high-priority biological risks. Fab’entech also plans to scale up production using the proven FabShield technology platform, which utilises polyclonal antibody fragments to neutralise pathogenic viruses and toxins, and drive global market expansion to meet rising demand.

The financing is supported by the European Commission’s Health Emergency Preparedness and Response Authority (HERA), established after the COVID-19 pandemic. HERA Invest, its €100m flagship initiative, aims at supporting health emergency prevention and preparedness in Europe, particularly in response to deliberate or natural emergence of biological threats which are among the most significant cross-border health threats HERA identified in 2022.

According to the EIB, Fabentech’s technology could play a vital role in ensuring rapid, effective responses to health emergencies.  “Investment in innovative companies such as Fab’entech is essential for strengthening health security in Europe,” stressed Ambroise Fayolle, Vice-President of the European Investment Bank. “With the joint support of HERA and the EIB through HERA Invest, Europe finances projects that advance emergency medical treatment against the most serious biological threats. This funding will enable Fab’entech to step up its work in this strategic area for Europe, strengthening our ability to respond to future health crises.”